Hundreds of millions of pounds could be freed up for front-line care if the NHS were to cut back on its use of agency staff, according to NHS Improvement. More: NHS could save £480m a year by cutting agency staff
read morePfizer is shutting down two clinical studies assessing the anti-myostatin monoclonal antibody domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD). More: Pfizer ends two Duchenne muscular dystrophy drug trials Source: News
read moreJanssen’s Darzalex has been approved in Europe for the first-line treatment of patients with multiple myeloma. More: Janssen bags new EU approval for Darzalex Source: News
read moreAstraZeneca’s experimental drug anifrolumab has failed to hit targets in a late stage trial in patients with lupus. More: AZ’ lupus therapy fails to hit the mark Source: News
read morePatients with the rare clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) have gained a new treatment option in Europe with the approval of Sanofi’s Cablivi. More: Sanofi’s Cablivi cleared for rare bleeding disorder Source: News
read moreOxford, UK-based Evox Therapeutics has raised £35 million to help advance its exosome-based therapeutics pipeline. More: Evox raises £35m for exosome therapeutics Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals